RepliCel Life Sciences Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a REPCF research report →
About the company
RepliCel Life Sciences Inc. , a biotechnology firm based in Vancouver, Canada, specializes in regenerative medicine. The company focuses on developing patient-specific cell therapies designed to address functional cellular deficits.
- CEO
- Andrew Schutte
- IPO
- 2010
- Employees
- 1
- HQ
- Vancouver, BC, CA
Price Chart
- Market Cap
- $7.00K
- P/E
- -9.38
- P/S
- 3.12
- P/B
- -0.21
- EV/EBITDA
- -5.33
- Div Yield
- 0.00%
- Gross Margin
- 100.00%
- Op Margin
- -101.77%
- Net Margin
- -27.50%
- ROE
- 1.86%
- ROIC
- 49.90%
- Revenue
- $353.44K · -0.08%
- Net Income
- $-401,629 · -312.81%
- EPS
- $-0.01 · -262.50%
- Op Income
- $237.84K
- FCF YoY
- 44.23%
- 52W High
- $0.04
- 52W Low
- $0.00
- 50D MA
- $0.00
- 200D MA
- $0.00
- Beta
- 0.43
- Avg Volume
- 664
Get TickerSpark's AI analysis on REPCF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our REPCF coverage
Recent articles, reports, and earnings notes.
No research on REPCF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate REPCF report →Similar companies
Peers in the same neighborhood.